Results involving NSCLC have not been published yet, but the first data from patients with colorectal cancer indicate a good tolerability of INCB001158 in association with pembrolizumab and an increase in CD8+ T cells accumulation within the tumor (158, 159). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.